WeTrials
Recruiting

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

What is this study?

This clinical trial is testing different targeted medications to see how well they treat meningiomas, which are tumors that form on the membranes covering the brain and spinal cord. The study focuses on tumors that are growing or getting worse, using special drugs designed to block the signals that help cancer cells grow and multiply.

Who can participate?

This study is designed for adults who have a meningioma that has progressed or come back after previous treatments and features specific gene changes. Your medical team will review your tumor's genetic profile to see which of the study medications is the best match for you.

What will happen?

If you join, you will be given one of the study medications designed to block tumor growth. Your health and the tumor's response will be closely monitored through regular check-ups and medical tests throughout the trial.

Where and when?

This study is currently recruiting participants and is taking place at locations in multiple cities, including Birmingham, Alabama, and Anchorage, Alaska.

Key Points
  • 1Testing targeted medications for progressive meningiomas
  • 2Focuses on tumors with specific gene mutations
  • 3Currently recruiting patients in Alabama and Alaska

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.